Short answer
Cencora (COR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Fiscal 2027 reporting shifts to Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
Cencora 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Fiscal 2027 reporting shifts to Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other
- Reorganization intended to strengthen execution and improve business visibility
- Other includes MWI Animal Health, Profarma, and selected PharmaLex operations under strategic review
- Exhibit 99.1 provides revised unaudited segment information for fiscal 2025 and 2026, enabling historical comparisons
Item EX-99.1 · Exhibit EX-99.1
- Revised FY2026 revenue $337.4B, up from revised FY2025 $321.3B
- Pharmaceutical Distribution and Services revenue $284.5B, operating income $2.74B
- Specialty Pharmaceutical and Provider Services revenue $45.4B, operating income $1.69B
- Specialty segment operating margin improved to 3.73% from 3.22%, the key profitability gain
- Total segment operating income $4.81B, up from revised FY2025 $4.22B
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cencora 8-K filings
Get the next COR 8-K as it lands
Follow COR for push alerts, or ask the research agent what this filing means.